Media ReleasesINOVIQ

View All INOVIQ News


INOVIQ & UQ Collaborate on Exosome-based Ovarian Cancer Test


* INOVIQ and The University of Queensland (UQ) expand collaboration to develop a world-first exosome-based ovarian cancer screening test
* UQ to develop exosome-based blood test for the earlier detection of ovarian cancer under a $2.7m Medical Research Future Fund (MRFF) grant
* INOVIQ to provide its EXO-NET® technology for fast, accurate and scalable exosome isolation in thousands of blood samples
* INOVIQ has the exclusive option to license rights to the development and commercialisation of UQ’s exosome-based early detection test for ovarian cancer to improve women’s health outcomes and help save lives 

Melbourne, Australia, 1 April 2022: INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) is excited to announce that it has expanded its collaboration with The University of Queensland (UQ) to develop a world-first exosome-based ovarian cancer screening test.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.